News
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.
The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...
Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...
The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.
After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...
The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback